Skip to main content
Media Coverage

Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal [Benzinga]

By November 12, 2024No Comments

Enveric Biosciences licenses its EB-002 drug candidate to MycoMedica Life Sciences, focusing on mental health treatment advancements. Enveric receives up to $62M in milestone payments and royalties, while prioritizing its neuroplastogen EB-003 for future development.

Full Article >>

Sign Up for Updates

© 2024 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.